DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases
Copyright © 2021. Published by Elsevier Inc..
Type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), and heart failure (HF)-along with their associated risk factors-have overlapping etiologies, and two or more of these conditions frequently occur in the same patient. Many recent cardiovascular outcome trials (CVOTs) have demonstrated the benefits of agents originally developed to control T2D, ASCVD, or CKD risk factors, and these agents have transcended their primary indications to confer benefits across a range of conditions. This evolution in CVOT evidence calls for practice recommendations that are not constrained by a single discipline to help clinicians manage patients with complex conditions involving diabetes, cardiorenal, and/or metabolic (DCRM) diseases. The ultimate goal for these recommendations is to be comprehensive yet succinct and easy to follow by the nonexpert-whether a specialist or a primary care clinician. To meet this need, we formed a volunteer task force comprising leading cardiologists, nephrologists, endocrinologists, and primary care physicians to develop the DCRM Practice Recommendations, a multispecialty consensus on the comprehensive management of the patient with complicated metabolic disease. The task force recommendations are based on strong evidence and incorporate practical guidance that is clinically relevant and simple to implement, with the aim of improving outcomes in patients with DCRM. The recommendations are presented as 18 separate graphics covering lifestyle therapy, patient self-management education, technology for DCRM management, prediabetes, cognitive dysfunction, vaccinations, clinical tests, lipids, hypertension, anticoagulation and antiplatelet therapy, antihyperglycemic therapy, hypoglycemia, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), ASCVD, HF, CKD, and comorbid HF and CKD, as well as a graphical summary of medications used for DCRM.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2022 |
|---|---|
| Erschienen: |
2022 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:36 |
|---|---|
| Enthalten in: |
Journal of diabetes and its complications - 36(2022), 2 vom: 15. Feb., Seite 108101 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Handelsman, Yehuda [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 14.03.2022 Date Revised 02.01.2023 published: Print-Electronic Citation Status MEDLINE |
|---|
| doi: |
10.1016/j.jdiacomp.2021.108101 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM334588847 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM334588847 | ||
| 003 | DE-627 | ||
| 005 | 20231225224029.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 231225s2022 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1016/j.jdiacomp.2021.108101 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1115.xml |
| 035 | |a (DE-627)NLM334588847 | ||
| 035 | |a (NLM)34922811 | ||
| 035 | |a (PII)S1056-8727(21)00325-1 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Handelsman, Yehuda |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a DCRM Multispecialty Practice Recommendations for the management of diabetes, cardiorenal, and metabolic diseases |
| 264 | 1 | |c 2022 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 14.03.2022 | ||
| 500 | |a Date Revised 02.01.2023 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Copyright © 2021. Published by Elsevier Inc. | ||
| 520 | |a Type 2 diabetes (T2D), chronic kidney disease (CKD), atherosclerotic cardiovascular disease (ASCVD), and heart failure (HF)-along with their associated risk factors-have overlapping etiologies, and two or more of these conditions frequently occur in the same patient. Many recent cardiovascular outcome trials (CVOTs) have demonstrated the benefits of agents originally developed to control T2D, ASCVD, or CKD risk factors, and these agents have transcended their primary indications to confer benefits across a range of conditions. This evolution in CVOT evidence calls for practice recommendations that are not constrained by a single discipline to help clinicians manage patients with complex conditions involving diabetes, cardiorenal, and/or metabolic (DCRM) diseases. The ultimate goal for these recommendations is to be comprehensive yet succinct and easy to follow by the nonexpert-whether a specialist or a primary care clinician. To meet this need, we formed a volunteer task force comprising leading cardiologists, nephrologists, endocrinologists, and primary care physicians to develop the DCRM Practice Recommendations, a multispecialty consensus on the comprehensive management of the patient with complicated metabolic disease. The task force recommendations are based on strong evidence and incorporate practical guidance that is clinically relevant and simple to implement, with the aim of improving outcomes in patients with DCRM. The recommendations are presented as 18 separate graphics covering lifestyle therapy, patient self-management education, technology for DCRM management, prediabetes, cognitive dysfunction, vaccinations, clinical tests, lipids, hypertension, anticoagulation and antiplatelet therapy, antihyperglycemic therapy, hypoglycemia, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH), ASCVD, HF, CKD, and comorbid HF and CKD, as well as a graphical summary of medications used for DCRM | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Research Support, Non-U.S. Gov't | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a Atherosclerotic cardiovascular disease | |
| 650 | 4 | |a Chronic kidney disease | |
| 650 | 4 | |a Clinical practice | |
| 650 | 4 | |a Consensus recommendations | |
| 650 | 4 | |a Heart failure | |
| 650 | 4 | |a Type 2 diabetes | |
| 650 | 7 | |a Hypoglycemic Agents |2 NLM | |
| 700 | 1 | |a Anderson, John E |e verfasserin |4 aut | |
| 700 | 1 | |a Bakris, George L |e verfasserin |4 aut | |
| 700 | 1 | |a Ballantyne, Christie M |e verfasserin |4 aut | |
| 700 | 1 | |a Beckman, Joshua A |e verfasserin |4 aut | |
| 700 | 1 | |a Bhatt, Deepak L |e verfasserin |4 aut | |
| 700 | 1 | |a Bloomgarden, Zachary T |e verfasserin |4 aut | |
| 700 | 1 | |a Bozkurt, Biykem |e verfasserin |4 aut | |
| 700 | 1 | |a Budoff, Matthew J |e verfasserin |4 aut | |
| 700 | 1 | |a Butler, Javed |e verfasserin |4 aut | |
| 700 | 1 | |a Dagogo-Jack, Samuel |e verfasserin |4 aut | |
| 700 | 1 | |a de Boer, Ian H |e verfasserin |4 aut | |
| 700 | 1 | |a DeFronzo, Ralph A |e verfasserin |4 aut | |
| 700 | 1 | |a Eckel, Robert H |e verfasserin |4 aut | |
| 700 | 1 | |a Einhorn, Daniel |e verfasserin |4 aut | |
| 700 | 1 | |a Fonseca, Vivian A |e verfasserin |4 aut | |
| 700 | 1 | |a Green, Jennifer B |e verfasserin |4 aut | |
| 700 | 1 | |a Grunberger, George |e verfasserin |4 aut | |
| 700 | 1 | |a Guerin, Chris |e verfasserin |4 aut | |
| 700 | 1 | |a Inzucchi, Silvio E |e verfasserin |4 aut | |
| 700 | 1 | |a Jellinger, Paul S |e verfasserin |4 aut | |
| 700 | 1 | |a Kosiborod, Mikhail N |e verfasserin |4 aut | |
| 700 | 1 | |a Kushner, Pamela |e verfasserin |4 aut | |
| 700 | 1 | |a Lepor, Norman |e verfasserin |4 aut | |
| 700 | 1 | |a Mende, Christian W |e verfasserin |4 aut | |
| 700 | 1 | |a Michos, Erin D |e verfasserin |4 aut | |
| 700 | 1 | |a Plutzky, Jorge |e verfasserin |4 aut | |
| 700 | 1 | |a Taub, Pam R |e verfasserin |4 aut | |
| 700 | 1 | |a Umpierrez, Guillermo E |e verfasserin |4 aut | |
| 700 | 1 | |a Vaduganathan, Muthiah |e verfasserin |4 aut | |
| 700 | 1 | |a Weir, Matthew R |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Journal of diabetes and its complications |d 1997 |g 36(2022), 2 vom: 15. Feb., Seite 108101 |w (DE-627)NLM012632503 |x 1873-460X |7 nnns |
| 773 | 1 | 8 | |g volume:36 |g year:2022 |g number:2 |g day:15 |g month:02 |g pages:108101 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.1016/j.jdiacomp.2021.108101 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 36 |j 2022 |e 2 |b 15 |c 02 |h 108101 | ||